Peter Hoang

Mr. Hoang is currently President & Chief Executive Officer and a member of the Board of Directors of TapImmune (Nasdaq: TPIV) a clinical-stage immuno-oncology company with ongoing clinical trials at the Mayo Clinic and Memorial Sloan-Kettering Cancer Center. Prior to TapImmune, he served as the Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM), a clinical-stage immuno-oncology and cell therapy company developing small molecule-controllable gene-modified T cell-based therapeutics. Previously, Mr. Hoang led the new venture formation and development effort as the Managing Director, Innovations in the Strategic Industry Ventures department for The University of Texas MD Anderson Cancer Center.

In addition to his executive management experience leading publicly traded biotechnology companies, Mr. Hoang has over 18 years of capital markets and deal-making experience in investment banking and venture capital, advising on over 100 transactions with an aggregate deal value of over $120 billion. Prior to MD Anderson, Peter was a senior investment banker, most recently as Managing Director and head of global healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He has also served in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. Mr. Hoang earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.